Sichuan Kelun Pharmaceutical Co., Ltd.

Sichuan Kelun Pharmaceutical Co., Ltd. saw its stock decline today, reaching an intraday low. Despite recent challenges, including a drop in net sales and operating cash flow, the company has shown resilience with a year-to-date gain and remains a significant player in the pharmaceuticals sector.

Sichuan Kelun Pharmaceutical Co., Ltd. saw its stock decline amid a broader market downturn, despite a positive one-month performance. The company reported a significant drop in net sales and low operating cash flow, while maintaining a market capitalization of CNY 36,978 million in the competitive pharmaceuticals sector.

Sichuan Kelun Pharmaceutical Co., Ltd. has shown strong stock performance, with notable gains over the past week and month, despite a decline in net sales and negative quarterly results. The company’s financial metrics indicate a market capitalization of CNY 36,978 million and a P/E ratio of 26.00.

Sichuan Kelun Pharmaceutical Co., Ltd. saw a significant intraday increase on March 10, 2026, contrasting with the modest gain of the China Shanghai Composite. Despite recent short-term gains, the company has struggled with declining net sales and negative quarterly results, reflecting challenges in its financial performance.

Sichuan Kelun Pharmaceutical Co., Ltd. saw a notable increase in its stock performance on March 6, 2026, reaching an intraday high. The company has outperformed the China Shanghai Composite in various timeframes, despite facing challenges such as a decline in net sales and underperformance over the past year.

Sichuan Kelun Pharmaceutical Co., Ltd. saw a notable intraday increase on March 5, 2026, despite a broader market decline. While the company has shown modest year-to-date growth, it faces challenges with slight declines over the past week and month, and significant losses over the past year and three years.